CXCR4 and amyotrophic lateral sclerosis: Here, we investigate if chronic administration of AMD3100, a pharmacological antagonist of CXCR4, to transgenic mice model of ALS (SOD1G93A) enables to (1) regulate inflammatory response by reducing proinflammatory cytokines and microglial activation, (2) prevent BSCB disruption, and if all together (3) may lead to extension in mice lifespan and improved well-being.